Cypherpunk Technologies Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Douglas E. Onsi
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 47 Thorndike Street Cambridge MA United States of America 02141
- IPO Date
- Jan 25, 2017
- CIK
- 0001509745
- Website
- cypherpunk.com
- Similar Companies
- Business
- Cypherpunk Technologies Inc. (NASDAQ: CYPH), formerly Leap Therapeutics Inc., is a clinical-stage biopharmaceutical company that develops targeted antibody therapies for cancer treatment and maintains a digital asset treasury strategy focused on privacy-preserving cryptocurrencies. The company offers DKN-01 (sirexatamab), a monoclonal antibody inhibiting Dickkopf-1 (DKK1) protein for esophagogastric, gynecologic, and colorectal cancers; FL-301, a monoclonal antibody targeting Claudin 18.2 for gastric and pancreatic cancers; and FL-501, a preclinical monoclonal antibody targeting growth and differentiation factor 15 (GDF-15). It conducts research and development through its wholly-owned subsidiary Leap Therapeutics Inc., with license agreements including Adimab LLC and BeiGene Ltd. for DKN-01 commercialization in select Asia-Pacific regions. Founded in 2011 and headquartered in Cambridge, Massachusetts, Cypherpunk Technologies operates primarily in the United States with a global clinical trial footprint. In November 2025, the company rebranded from Leap Therapeutics following a $58.88 million private placement led by Winklevoss Capital Management, expanded its leadership team, and launched a Zcash accumulation strategy; it acquired 203,775 ZEC tokens for $50 million at $245 per token and later added holdings worth $18 million at $291 per token, targeting 5% of Zcash supply as a long-term strategic asset.
Cypherpunk Technologies Inc. (CYPH) Shareholder/Analyst Call Prepared Remarks Transcript
Cypherpunk Technologies Reports First Quarter 2026 Financial Results
Cypherpunk Increases its Zcash Stake, Launches New Website and Investor Dashboard
Cypherpunk Reports Full Year 2025 Financial Results
Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)
Cypherpunk Adds Arjun Khemani as Strategic Advisor
Cypherpunk Accelerates Zcash Accumulation; Increases Treasury Holdings to 290,062.67 ZEC
Josh Swihart, ECC CEO, Joins Cypherpunk as Strategic Advisor
Cypherpunk Technologies Inc. (CYPH) Leap Therapeutics, Inc. - Shareholder/Analyst Call Prepared Remarks Transcript
Cypherpunk Taps Zcash Founder Zooko as Strategic Advisor
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy
Leap Therapeutics Presents Final Data from DeFianCe Study at ESMO 2025
Leap Therapeutics Announces Closing of $58.88 Million Private Placement in Cash Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics Announces $58.88 Million Private Placement in Cash Commitments Led by Winklevoss Capital to Initiate a Digital Asset Treasury Strategy
Leap Therapeutics to Present Final Clinical Data from Part B of the DeFianCe Study at the ESMO Congress 2025
Leap Therapeutics Reports Second Quarter 2025 Financial Results
Leap Therapeutics Reports Updated Clinical Data from Sirexatamab Colorectal Cancer Study and Announces Exploration of Strategic Alternatives
Leap Therapeutics Reports First Quarter 2025 Financial Results
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel GDF-15 Neutralizing Antibody, at the AACR 2025 Annual Meeting